Difference between revisions of "CT Angiography Biomarker Ctte"
m (→Meetings) |
|||
| Line 6: | Line 6: | ||
'''Recent Call Summaries:''' | '''Recent Call Summaries:''' | ||
| + | *[[Media: 2018 08 13 QIBA CT Angiography_FINAL.pdf | August 13, 2018]] | ||
*[[Media: 2018 07 30 QIBA CT Angiography_FINAL.pdf | July 30, 2018]] | *[[Media: 2018 07 30 QIBA CT Angiography_FINAL.pdf | July 30, 2018]] | ||
*[[Media: 2018 07 09 QIBA CT Angiography_FINAL.pdf | July 9, 2018]] | *[[Media: 2018 07 09 QIBA CT Angiography_FINAL.pdf | July 9, 2018]] | ||
Revision as of 14:34, 16 August 2018
Co-chairs: Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT Secretary: Julie Lisiecki
Meetings
Recent Call Summaries:
Project Snapshot - CT Angiography
The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).
Excerpt from the biomarker committee submission form:
The proposed QIBA Atherosclerosis Biomarkers Committee (ABC) will be composed of members from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Furthermore, stakeholders from different manufacturers will be included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee will develop technical performance standards to serve as atherosclerosis compositional biomarkers. Moreover, we will involve stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.
Profile Development
Groundwork Projects
Reference Materials
- QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler} March 27, 2018 (PDF)